$RVV $RVVTF - Great Post from Bobby - Yahoo Finance !I could be misreading the situation but it feels like there is a lot of subtle signaling going on here from MF and Revive. They cannot officially disclose the efficacy results on Bucillamine yet, however a number of recent actions, updates and disclosures heavily hint that the company is messaging to the market to hang in there, positive results are coming. You have MF purchasing shares on the public market, the investor deck updated with lots of focus on Bucillamine, a Twitter campaign with big pharma hashtags, massive ramp up of the number of sites participating in the Bucillamine trials, etc. I feel like they are trying to scream as loud as they ethically and legally can that very positive news is coming. Unfortunately, I think the (mis-)communication around interim efficacy results had a lot people expecting an efficacy update last month which never materialized and that is one of the big reasons for the recent downward price pressure on this stock. Markets are all about expectations and where you land relative to them. I'm still personally very optimistic and holding long on RVV!
While the Bucillamine efficacy results are only known to the Independent Data and Safety Monitoring Board (“DSMB”) at this time, I believe they are solely responsible for recommendations on continuation, stopping or changes to the conduct of the study, Given that we're growing from 14 to 50 clinical sites, the DSMB would have almost certainly been seeing very positive outcomes in the study to-date to recommend this rapid rate of expansion. While it could be argued that they may have recommended the site increase because the results to date are not statistically significant to draw conclusions (Bucillamine vs placebo), I would imagine even a modest 1.5x of sites would have remedied that. But a more than 3.5x increase signals (to me at least) that results so far are promising and that the study should be expedited.